GO
Loading...

Biotechnology

More

  • CNBC biotech & pharma reporter Meg Tirrell talks to Richard Pazdur, the FDA's cancer czar about how far we've come in cancer treatment, breakthrough designations and if chemotherapy will soon be a thing of the past.

  • ASCO cancer care conference kicks off  Friday, 30 May 2014 | 1:01 PM ET

    In the U.S., half of all men and a third of all women will develop cancer in their lifetimes. CNBC's Meg Tirrell reports which stocks analysts are eyeing into the conference.

  • War on cancer  Thursday, 29 May 2014 | 1:38 PM ET

    The big topic at this year's cancer care conference ASCO will be immunotherapy drugs. CNBC's Meg Tirrell explains how these drugs work.

  • Valeant raises Allergan bid  Wednesday, 28 May 2014 | 10:54 AM ET

    Valeant is upping its offer for Allergan in a proposal that could now be worth more than $50 billion, reports CNBC's Meg Tirrell.

  • Why Mesoblast is big on stem-cell therapy  Tuesday, 27 May 2014 | 11:38 PM ET

    Silviu Itescu, CEO of Mesoblast, highlights sources of growth that may propel stem-cell therapy into a multi billion-dollar market by 2020.

  • How not to fear biotech  Thursday, 15 May 2014 | 1:24 PM ET

    Discussing hot picks in the biotech space, with Matthew Roden, UBS executive director.

  • Big gains for Nasdaq  Monday, 12 May 2014 | 11:59 AM ET

    CNBC's Seema Mody reveals what stocks and sectors are driving the Nasdaq rally today.

  • CNBC's Meg Tirrell speaks to Ken Frazier, Merck chaiman & CEO, about selling the company's consumer unit to Bayer. Frazier also gives his stance on mega-mergers and U.S corporate tax rate.

  • 'Super bug' spreads  Monday, 5 May 2014 | 1:32 PM ET

    CNBC's Meg Tirrell reports the World Health Organization has confirmed about 262 cases of the MERS virus, of which 93 people have died. Dr. William Schaffner of the Vanderbilt School of Medicine, provides insight.

  • End-game of polio 'fragile': Expert  Monday, 5 May 2014 | 1:32 PM ET

    Dr. William Schaffner of the Vanderbilt School of Medicine, addresses the latest polio outbreaks, and the importance of vaccinating children.

  • Is Apple hiring spree a sign new device is coming? Monday, 5 May 2014 | 11:28 AM ET
    Apple CEO Tim Cook looks on at an Apple Store on September 20, 2013 in Palo Alto, California.

    Apple is expanding to medical technology. The company is recruiting a team of medical executives and has offered hints of the iWatch and others.

  • AstraZeneca rejects new Pfizer bid  Friday, 2 May 2014 | 9:07 AM ET

    AstraZeneca has rejected Pfizer's sweetened bid claiming it undervalues the company. The "Squawk on the Street" news team shares their thoughts on the latest bid and the U.S. tax code.

  • Cramer: Pfizer solution loved by market  Tuesday, 29 Apr 2014 | 9:07 AM ET

    The "Squawk on the Street" news team break down Merck's quarterly earnings beat and discuss the state of big pharma and taxes.

  • Pfizer, AstraZeneca about drug pipeline: Pro  Monday, 28 Apr 2014 | 11:23 AM ET

    Discussing Pfizer's push for a $100 billion deal for AstraZeneca, with Seamus Fernandez Leerink Partners managing director.

  • Pfizer pushes for $100 billion AstraZeneca deal  Monday, 28 Apr 2014 | 10:10 AM ET

    Pfizer is working on its next move in a potential $100 billion battle for AstraZeneca after having two bids rejected. CNBC's Meg Tirrell reports buying AstraZeneca would boost Pfizer's cancer drug pipeline.

  • Analyst suggests Allergan buy Shire  Thursday, 24 Apr 2014 | 12:41 PM ET

    CNBC's Meg Tirrell reports a Cowen analyst is suggesting Allergan buy ADHD drug maker Shire. The FMHR traders, provide perspective.

  • Biogen barreling down on Alzheimer's  Wednesday, 23 Apr 2014 | 3:33 PM ET

    CNBC's Meg Tirrell speaks with George Scangos, Biogen Idec CEO, about the drug maker's fight against MS and Alzheimer's. Scangos also comments on Valeant's bid for Alllergan.

  • Tech & biotech plays for your portfolio  Wednesday, 23 Apr 2014 | 10:04 AM ET

    Kevin Caron, Stifel Private Client Group market strategist, and Doug MacKay, Broadleaf Partners president & CIO, discuss signs of a tech bubble and share their investment strategies on hot technology stocks.

  • Cramer: Gilead crux of health care in US  Wednesday, 23 Apr 2014 | 9:08 AM ET

    Record sales of a new hepatitis C drug pushed the first-quarter earnings of Gilead Sciences beyond expectations. The "Squawk on the Street" news team break down its quarterly beat.

  • Biotech earnings: All eyes on Gilead  Tuesday, 22 Apr 2014 | 3:45 PM ET

    CNBC's Meg Tirrell previews the earnings of biotech players Gilead and Amgen. Tirrell explains why investors will be focusing on Gilead's Sovaldi sales.